- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nuvation Bio Inc (NUVB)
Nuvation Bio Inc stock price live, this page displays NYSE NUVB stock exchange data. View the NUVB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nuvation Bio Inc real time stock price chart below.
What Is the Nuvation Bio Inc Stock Price Today?
The Nuvation Bio Inc stock price today is 4.774.
What Is the Stock Symbol for Nuvation Bio Inc?
The stock symbol for Nuvation Bio Inc is "NUVB."
What Stock Exchange Does Nuvation Bio Inc Trade On?
Nuvation Bio Inc is listed and trades on the NYSE stock exchange.
Is Nuvation Bio Inc a Good Stock to Buy?
Determining whether Nuvation Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NUVB quote. (ISIN: US67080N1019)
What Is the Nuvation Bio Inc Stock Price Today?
The Nuvation Bio Inc stock price today is 4.774.
What Is the Stock Symbol for Nuvation Bio Inc?
The stock symbol for Nuvation Bio Inc is "NUVB."
What Stock Exchange Does Nuvation Bio Inc Trade On?
Nuvation Bio Inc is listed and trades on the NYSE stock exchange.
Is Nuvation Bio Inc a Good Stock to Buy?
Determining whether Nuvation Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NUVB quote. (ISIN: US67080N1019)
4.774
+0.364(+8.24%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.120
4.825
52 wk Range
1.570
9.750
NUVB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.1204.825
52 wk Range
1.5709.750
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NUVB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
12.333
Upside
+158.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.333
(+158.34% Upside)
Nuvation Bio Inc SWOT Analysis
IBTROZI's Triumph | Nuvation Bio's transition to a commercial-stage company with FDA approval of IBTROZI for ROS1-positive NSCLC marks a pivotal moment in oncology treatment |
Market Dynamics | Explore IBTROZI's competitive edge in ROS1+ NSCLC treatment, its pricing strategy, and its potential to reshape the market landscape |
Financial Fortitude | Delve into Nuvation Bio's robust financial position, with analyst price targets ranging from $5 to $10 per share and projected peak sales of $2.5 billion globally |
Future Horizons | Uncover Nuvation Bio's promising pipeline, including safusidenib and NUV-1511, poised to expand the company's oncology portfolio and market presence |
Nuvation Bio Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue reached $83.2M, exceeding forecasts by 25.69%; EPS of $0.01 met expectations with stock rising 0.22% after-hours.
- Product revenue grew 18% quarter-over-quarter, driven by increased Ibtrozi sales for ROS1-positive NSCLC treatment and patient retention.
- Strategic Eisai partnership contributed $60M upfront payment; company maintains strong liquidity with $533.7M in cash and securities.
- Company projects continued growth with $30M milestone payment expected upon European Ibtrozi approval in 2027; expanded into Japan market.
- CEO emphasized no need for external financing while focusing on pipeline advancement; risks include regulatory hurdles and market competition.
Last Updated: 2026-05-04, 05:46 p/m
Read Full TranscriptEarnings
Latest Release
May 04, 2026
EPS / Forecast
0.01 / 0.01
Revenue / Forecast
83.23M / 66.22M
Compare NUVB to Peers and Sector
Metrics to compare | NUVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.1x | −2.1x | −0.5x | |
PEG Ratio | −0.11 | 0.12 | 0.00 | |
Price/Book | 5.4x | 1.6x | 2.6x | |
Price / LTM Sales | 26.4x | 3.4x | 3.3x | |
Upside (Analyst Target) | 154.5% | 45.9% | 47.1% | |
Fair Value Upside | Unlock | 23.3% | 6.2% | Unlock |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Nuvation Bio (NUVB) Stock Price Today?
The Nuvation Bio stock price today is 4.774 USD.
What Stock Exchange Does Nuvation Bio Trade On?
Nuvation Bio is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Nuvation Bio?
The stock symbol for Nuvation Bio is "NUVB."
What Is the Nuvation Bio Market Cap?
As of today, Nuvation Bio market cap is 1.640B USD.
What Is Nuvation Bio's Earnings Per Share (TTM)?
The Nuvation Bio EPS (TTM) is -0.599.
When Is the Next Nuvation Bio Earnings Date?
Nuvation Bio will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is NUVB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Nuvation Bio Stock Split?
Nuvation Bio has split 0 times.
How Many Employees Does Nuvation Bio Have?
Nuvation Bio has 298 employees.
What is the current trading status of Nuvation Bio (NUVB)?
As of May 05, 2026, Nuvation Bio (NUVB) is trading at a price of 4.774 USD, with a previous close of 4.410 USD. The stock has fluctuated within a day range of 4.120 USD to 4.825 USD, while its 52-week range spans from 1.570 USD to 9.750 USD.
What Is Nuvation Bio (NUVB) Price Target According to Analysts?
The average 12-month price target for Nuvation Bio is 12.333 USD, with a high estimate of 20 USD and a low estimate of 7 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +158.34% Upside potential.
What Is the NUVB Premarket Price?
NUVB's last pre-market stock price is 4.230 USD. The pre-market share volume is 96,530.000, and the stock has decreased by -0.180, or -4.080%.
What Is the NUVB After Hours Price?
NUVB's last after hours stock price is 4.540 USD, the stock has decreased by 0.130, or 2.950%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.